TESARO, Inc. (NASDAQ:TSRO) – Analysts at Oppenheimer Holdings issued their FY2021 EPS estimates for TESARO in a report released on Wednesday. Oppenheimer Holdings analyst L. Cann expects that the biopharmaceutical company will post earnings of $14.60 per share for the year. Oppenheimer Holdings has a “Buy” rating and a $199.00 price objective on the stock.
TESARO (NASDAQ:TSRO) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) EPS for the quarter, missing the Zacks’ consensus estimate of ($2.52) by ($0.30). TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. The business had revenue of $29.50 million during the quarter, compared to analysts’ expectations of $18.61 million. During the same quarter in the prior year, the firm earned ($1.28) EPS. TESARO’s revenue for the quarter was down 17.6% compared to the same quarter last year.
WARNING: “Oppenheimer Holdings Weighs in on TESARO, Inc.’s FY2021 Earnings (TSRO)” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://www.com-unik.info/2017/11/01/oppenheimer-holdings-weighs-in-on-tesaro-inc-s-fy2021-earnings-tsro.html.
Several other brokerages have also weighed in on TSRO. BidaskClub lowered TESARO from a “sell” rating to a “strong sell” rating in a research report on Wednesday, July 19th. Wedbush reaffirmed an “outperform” rating and issued a $160.00 target price on shares of TESARO in a research report on Monday, September 11th. ValuEngine lowered TESARO from a “hold” rating to a “sell” rating in a research report on Monday, July 17th. Barclays PLC assumed coverage on TESARO in a research report on Monday, October 23rd. They issued an “equal weight” rating and a $135.00 target price on the stock. Finally, Gabelli assumed coverage on TESARO in a research report on Friday, July 7th. They issued a “buy” rating and a $175.00 target price on the stock. Three equities research analysts have rated the stock with a sell rating, eleven have given a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $166.10.
Several institutional investors have recently made changes to their positions in TSRO. Janus Henderson Group PLC acquired a new stake in shares of TESARO during the second quarter valued at about $100,301,000. PointState Capital LP acquired a new stake in shares of TESARO during the second quarter valued at about $85,971,000. Pictet Asset Management Ltd. grew its stake in shares of TESARO by 58.1% during the third quarter. Pictet Asset Management Ltd. now owns 630,904 shares of the biopharmaceutical company’s stock valued at $81,450,000 after acquiring an additional 231,799 shares in the last quarter. Pioneer Investment Management Inc. grew its stake in shares of TESARO by 195.6% during the second quarter. Pioneer Investment Management Inc. now owns 317,753 shares of the biopharmaceutical company’s stock valued at $44,441,000 after acquiring an additional 210,273 shares in the last quarter. Finally, BlackRock Inc. grew its stake in shares of TESARO by 5.7% during the second quarter. BlackRock Inc. now owns 3,605,247 shares of the biopharmaceutical company’s stock valued at $504,230,000 after acquiring an additional 195,590 shares in the last quarter.
In other news, VP Edward C. English sold 10,862 shares of the firm’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $134.92, for a total transaction of $1,465,501.04. Following the completion of the sale, the vice president now directly owns 6,258 shares in the company, valued at $844,329.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Martin H. Jr. Huber sold 592 shares of the firm’s stock in a transaction dated Friday, September 22nd. The shares were sold at an average price of $118.60, for a total value of $70,211.20. Following the sale, the senior vice president now owns 6,943 shares of the company’s stock, valued at $823,439.80. The disclosure for this sale can be found here. Insiders have sold 35,692 shares of company stock valued at $4,628,976 over the last 90 days. Insiders own 34.60% of the company’s stock.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
What are top analysts saying about TESARO Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for TESARO Inc. and related companies.